Cidara Therapeutics assumed with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage of Cidara Therapeutics (CDTX) with an Overweight rating. Cidara’s lead asset CD388, an anti-viral that targets neuraminidase, an essential surface receptor specific to the influenza virus, has the potential to be a game-changing, preventative therapy targeting a broad range of influenza strains, and could surpass $2B peak U.S. sales, the analyst tells investors in a research note. Cantor says that CD388 is designed to address many limitations of currently approved therapies, and that its active ingredient zanamivir has not been shown to acquire viral resistance.